JP2017510552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510552A5 JP2017510552A5 JP2016550760A JP2016550760A JP2017510552A5 JP 2017510552 A5 JP2017510552 A5 JP 2017510552A5 JP 2016550760 A JP2016550760 A JP 2016550760A JP 2016550760 A JP2016550760 A JP 2016550760A JP 2017510552 A5 JP2017510552 A5 JP 2017510552A5
- Authority
- JP
- Japan
- Prior art keywords
- modulator
- fibrosis
- composition
- item
- regulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937272P | 2014-02-07 | 2014-02-07 | |
| US61/937,272 | 2014-02-07 | ||
| US201462010004P | 2014-06-10 | 2014-06-10 | |
| US62/010,004 | 2014-06-10 | ||
| US201462037497P | 2014-08-14 | 2014-08-14 | |
| US62/037,497 | 2014-08-14 | ||
| PCT/US2015/014939 WO2015120350A2 (en) | 2014-02-07 | 2015-02-07 | Compositions and methods for treating fibrotic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017510552A JP2017510552A (ja) | 2017-04-13 |
| JP2017510552A5 true JP2017510552A5 (https=) | 2018-03-22 |
Family
ID=52684645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550760A Pending JP2017510552A (ja) | 2014-02-07 | 2015-02-07 | 線維性疾患を治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9993494B2 (https=) |
| EP (1) | EP3102703A2 (https=) |
| JP (1) | JP2017510552A (https=) |
| CN (1) | CN106102775A (https=) |
| AU (1) | AU2015213721B2 (https=) |
| CA (1) | CA2938592A1 (https=) |
| WO (1) | WO2015120350A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2017189837A1 (en) * | 2016-04-29 | 2017-11-02 | The Trustees Of The University Of Pennsylvania | Protein kinase rna-like endoplasmic reticulum kinase (perk) inhibitors for prevention and/or treatment of lung injury and/or inflammation |
| US10894960B2 (en) | 2016-08-30 | 2021-01-19 | Children's Hospital Medical Center | Compositions and methods for nucleic acid transfer |
| CN109982693A (zh) | 2016-09-22 | 2019-07-05 | 香港大学 | 细胞异常分化和isr相关疾病的预防和治疗方法 |
| WO2018149978A1 (en) * | 2017-02-16 | 2018-08-23 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | ALTERNATIVE ACTIVATION OF MACROPHAGES (M2 CELLS) THROUGH THE POLYAMINE-eIF5a-HYPUSINE AXIS |
| US12411144B2 (en) | 2017-03-22 | 2025-09-09 | Children's Hospital Medical Center | Compositions and methods for treatment of lung function |
| CN106983738B (zh) * | 2017-04-13 | 2020-03-10 | 深圳市润佳通科技有限公司 | 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防皮肤疾病的药物中的应用 |
| CA3063563A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Compositions and methods for an improved antitumor immune response |
| CN107260730B (zh) * | 2017-05-31 | 2019-10-22 | 上海市东方医院 | 组蛋白去乙酰化酶hdac6的抑制剂在制备防治腹膜透析后腹膜纤维化的药物中的用途 |
| EP3747438A1 (en) | 2017-07-24 | 2020-12-09 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
| EP3659609B1 (en) | 2017-07-28 | 2024-05-08 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent for fibrosis |
| CN107326093B (zh) * | 2017-09-04 | 2020-01-21 | 东南大学 | 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用 |
| CN107916254B (zh) * | 2017-11-29 | 2020-05-12 | 武汉大学 | Homer1单克隆抗体及其应用 |
| CN108192984B (zh) * | 2018-02-13 | 2020-06-23 | 浙江大学 | 与湖羊肉质性状相关的分子标记及特异性引物对和应用 |
| WO2019180664A1 (en) * | 2018-03-21 | 2019-09-26 | The University Of Hong Kong | Method for preventing or modulating fibrosis and fibrotic response associated with the integrated stress response |
| AU2020299362B2 (en) | 2019-07-02 | 2026-02-26 | Effector Therapeutics, Inc. | EiF4e-inhibiting 4-OXO-3,4-dihydropyrido(3,4-d)pyrimidine compounds |
| KR102100163B1 (ko) | 2019-09-24 | 2020-04-13 | 테고사이언스 (주) | 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물 |
| CN111228464A (zh) * | 2020-02-28 | 2020-06-05 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 广谱抗冠状病毒的多肽及其用途 |
| CN113679841A (zh) * | 2020-05-19 | 2021-11-23 | 上海市同济医院 | 一种磷脂酶d1(pld1)基因及其抑制剂在肝纤维化防治中的应用 |
| US20230181582A1 (en) | 2020-05-22 | 2023-06-15 | Qx Therapeutics Inc. | Compositions and methods for treating lung injuries associated with viral infections |
| CA3180229A1 (en) * | 2020-05-29 | 2021-12-02 | Cathy A. Swindlehurst | Biarylsulfonamides and pharmaceutical compositions thereof, and their use for treating fibrotic lung disease |
| EP4217378A4 (en) * | 2020-10-08 | 2025-02-26 | The Trustees Of Dartmouth College | Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions |
| CA3207882A1 (en) * | 2021-01-15 | 2022-07-21 | Children's Hospital Medical Center | Methods for optimizing cftr-modulator therapy |
| GB202109534D0 (en) * | 2021-07-01 | 2021-08-18 | Anglia Ruskin Univ Higher Education Corporation | Treatment of scarring |
| US20250090523A1 (en) * | 2021-07-22 | 2025-03-20 | Shanghai Synvida Biotechnology Co. Ltd. | Pharmaceutical composition or drug kit for alleviating or treating fibrotic diseases, and use thereof |
| CN118804976A (zh) * | 2021-12-17 | 2024-10-18 | 雷杰纳荣制药公司 | 用整联蛋白亚基α1(ITGA1)抑制剂治疗肺部疾患 |
| CN115558712B (zh) * | 2022-09-22 | 2026-03-24 | 华中科技大学同济医学院附属协和医院 | Fam177a1的新用途 |
| CN117281906A (zh) * | 2023-10-18 | 2023-12-26 | 浙江大学 | Csrnp1抑制剂在制备治疗肝脏缺血再灌注损伤药物中的应用 |
| WO2025092340A1 (zh) * | 2023-11-03 | 2025-05-08 | 成都嘉葆药银医药科技有限公司 | 吡咯并三嗪类化合物在制备预防和/或治疗纤维化或其相关疾病的药物中的应用 |
| CN117589999A (zh) * | 2023-11-17 | 2024-02-23 | 深圳市人民医院 | Pfkp作为慢性肾脏疾病治疗靶点的应用及其抑制剂 |
| EP4714443A1 (en) * | 2024-09-19 | 2026-03-25 | Fundación Pública Galega Instituto de Investigación Sanitaria de Santiago de Compostela | Heme-regulated inhibitor kinase activators for the treatment of neurological disorders |
| CN120789266A (zh) * | 2025-09-10 | 2025-10-17 | 山东第一医科大学第一附属医院(山东省千佛山医院) | Eif3a抑制剂在制备治疗肝纤维化药物中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046219A (en) | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| EP1693059A1 (en) | 2005-02-22 | 2006-08-23 | Deutsches Krebsforschungszentrum | Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases |
| JP4512828B2 (ja) | 2005-04-12 | 2010-07-28 | 国立大学法人 千葉大学 | 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット |
| WO2007027509A2 (en) * | 2005-08-31 | 2007-03-08 | Biogen Idec Ma Inc. | Evaluating and treating scleroderma |
| GB0617117D0 (en) | 2006-08-31 | 2006-10-11 | Renovo Ltd | Method of diagnosis |
| US20090004668A1 (en) * | 2007-06-22 | 2009-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Pre-miRNA loop-modulated target regulation |
| US7550300B1 (en) | 2007-11-29 | 2009-06-23 | Capgen Sciences, Inc. | Prediction of bare metal stent restenosis |
| US8486865B2 (en) | 2008-11-03 | 2013-07-16 | The Regents Of The University Of California | Methods for detecting modification resistant nucleic acids |
| MX2011005482A (es) | 2008-12-05 | 2011-06-16 | Intermed Discovery Gmbh | Inhibidores de acumulacion de la proteina del factor 1 inducible por hipoxia. |
| US20100152531A1 (en) * | 2008-12-11 | 2010-06-17 | Paracor Medical, Inc. | Implantable medical device for drug delivery and method of use |
| US20110319338A1 (en) | 2008-12-18 | 2011-12-29 | The Board Of Regents Of The University Of Texas System | Peptides that bind eukaryotic translation initiation factor 4e |
| US20120282276A1 (en) | 2009-11-05 | 2012-11-08 | The Regents Of The University Of Michigan | Biomarkers predictive of progression of fibrosis |
| FR2954943B1 (fr) * | 2010-01-07 | 2013-03-01 | Sanofi Aventis | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
| US8877188B2 (en) | 2010-05-04 | 2014-11-04 | The Brigham And Women's Hospital, Inc. | Detection and treatment of non-dermal fibrosis |
| WO2011140334A2 (en) | 2010-05-06 | 2011-11-10 | Trustees Of Boston University | Compounds, methods of making or identifying compounds, and uses thereof |
| JP5855095B2 (ja) | 2010-06-07 | 2016-02-09 | ノボメディックス, エルエルシーNovomedix, Llc | フラニル化合物およびその使用 |
| CA2803880C (en) | 2010-06-28 | 2018-09-25 | President And Fellows Of Harvard College | Compounds for the inhibition of cellular proliferation |
| WO2014085633A1 (en) | 2012-11-30 | 2014-06-05 | Novomedix, Llc | Substituted biaryl sulfonamides and the use thereof |
| DK2954323T3 (da) | 2013-02-07 | 2020-07-20 | Univ California | Anvendelse af translationsprofilering til identifikation af målmolekyler til terapeutisk behandling |
| WO2014124412A2 (en) | 2013-02-11 | 2014-08-14 | President And Fellows Of Harvard College | Methods and compounds for the inhibition of cellular proliferation |
-
2015
- 2015-02-07 JP JP2016550760A patent/JP2017510552A/ja active Pending
- 2015-02-07 AU AU2015213721A patent/AU2015213721B2/en not_active Ceased
- 2015-02-07 US US14/616,690 patent/US9993494B2/en active Active
- 2015-02-07 CA CA2938592A patent/CA2938592A1/en not_active Abandoned
- 2015-02-07 WO PCT/US2015/014939 patent/WO2015120350A2/en not_active Ceased
- 2015-02-07 EP EP15710297.1A patent/EP3102703A2/en not_active Withdrawn
- 2015-02-07 CN CN201580007480.7A patent/CN106102775A/zh active Pending
-
2018
- 2018-05-07 US US15/973,281 patent/US10576098B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510552A5 (https=) | ||
| US10576098B2 (en) | Compositions and methods for treating fibrotic disease | |
| Sun et al. | Cellular senescence: the sought or the unwanted? | |
| Bonelli et al. | Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells | |
| Escudier et al. | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | |
| Asghar et al. | Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? | |
| Cho et al. | Targeting HIF2 in clear cell renal cell carcinoma | |
| JP7367910B2 (ja) | がんの処置 | |
| US20190136321A1 (en) | Use of translational profiling to identify target molecules for therapeutic treatment | |
| CN119235863A (zh) | 用于免疫病况的治疗的mk2途径抑制剂的口服组合物 | |
| KR20160048196A (ko) | 교모세포종의 치료를 위한 진단 방법 및 조성물 | |
| Li et al. | Dexamethasone combined with berberine is an effective therapy for bleomycin-induced pulmonary fibrosis in rats | |
| JP2018516244A5 (https=) | ||
| Srikanthan et al. | Creating a biomarker panel for early detection of chemotherapy related cardiac dysfunction in breast cancer patients | |
| Cai et al. | C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation | |
| Dey et al. | CopA3 peptide inhibits MDM2-p53 complex stability in colorectal cancers and activates p53 mediated cell death machinery | |
| Lemay et al. | Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies | |
| Russell et al. | Inhibiting autophagy in renal cell cancer and the associated tumor endothelium | |
| Powers et al. | Activation of the integrated stress response by the developmental HSF1 pathway inhibitor NXP800 | |
| US20200360375A1 (en) | Small molecule wnt inhibitor as treatment for dyslipidemia | |
| JP2016088926A5 (https=) | ||
| BR112014024230A8 (pt) | Polipeptídeo, derivado do polipeptídeo, ácido nucleico, vetor, célula hospedeira, método de produção do polipeptídeo, composição farmacêutica, kit, método de inibição de atividade de notch, método de tratamento de uma doença, anticorpo isolado, método de o aumento da atividade de notch | |
| Gadgeel | MS05. 03 Notch Signalling | |
| Ri et al. | The KLF6 super-enhancer determines KLF6 sensitivity to BRD4 inhibitors in human hepatoma (HepG2) cells | |
| Wang et al. | Aging modulation of the immune system and immunotherapy efficacy in cancer |